

ADHD Medication and Substance-Related Problems

Patrick D. Quinn, Ph.D., Zheng Chang, Ph.D., Kwan Hur, Ph.D., Robert D. Gibbons, Ph.D., Benjamin B. Lahey, Ph.D., Martin E. Rickert, Ph.D., Arvid Sjölander, Ph.D., Paul Lichtenstein, Ph.D., Henrik Larsson, Ph.D., Brian M. D'Onofrio, Ph.D.

Objective: Substance use disorders are major contributors to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet associations between pharmacological ADHD treatment and substance-related problems remain unclear. This study investigated concurrent and long-term associations between ADHD medication treatment and substance-related events.

Method: The authors analyzed 2005–2014 commercial health care claims from 2,993,887 (47.2% female) adolescent and adult ADHD patients. Within-individual analyses compared the risk of substance-related events (i.e., emergency department visits related to substance use disorders) during months in which patients received prescribed stimulant medication or atomoxetine relative to the risk during months in which they did not.

Results: In adjusted within-individual comparisons, relative to periods in which patients did not receive ADHD medication, male patients had 35% lower odds of concurrent

substance-related events when receiving medication (odds ratio=0.65, 95% CI=0.64–0.67), and female patients had 31% lower odds of concurrent substance-related events (odds ratio=0.69, 95% CI=0.67–0.71). Moreover, male patients had 19% lower odds of substance-related events 2 years after medication periods (odds ratio=0.81, 95% CI=0.78–0.85), and female patients had 14% lower odds of substance-related events 2 years after medication periods (odds ratio=0.86, 95% CI=0.82–0.91). Sensitivity analyses supported most findings but were less consistent for long-term associations among women.

Conclusions: These results provide evidence that receiving ADHD medication is unlikely to be associated with greater risk of substance-related problems in adolescence or adulthood. Rather, medication was associated with lower concurrent risk of substance-related events and, at least among men, lower long-term risk of future substance-related events.

Am J Psychiatry 2017; 174:877–885; doi: 10.1176/appi.ajp.2017.16060686

Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder, affecting 2.6%–4.5% of youths worldwide and continuing, for many, into adolescence and adulthood (1–3). Prospective studies show that the risk of substance use disorders is a persisting concern in ADHD (4, 5) at least in part because the two disorders share genetic influences (6–8). Substance use disorders contribute substantially to elevated mortality rates among patients with ADHD (9).

Understanding the association between pharmacological ADHD treatment and substance-related problems is essential for evaluating the potential benefit of such treatment. Stimulant medications are effective in reducing ADHD symptoms in the short term and are recognized as the first-line treatment option for school-aged children, adolescents, and adults (10–12). Medication associations with substance-related problems, however, have been widely debated (13). Some early research suggested a sensitization hypothesis, wherein exposure to stimulants might increase risk for substance-related problems (14). This possibility continues to

be supported by some animal studies, particularly during adolescence (15). Further clinical studies, in contrast, have not found support for medication-induced increases in risk. For example, follow-up data from the Multimodal Treatment Study of Attention Deficit Hyperactivity Disorder and a meta-analysis showed no medication associations with substance use or problems (16, 17). In fact, several more recent studies have found that medication treatment is associated with decreased substance-related risk (18–20). At present, uncertainty remains regarding the extent to which medication treatment affects substance-related problems (21–24).

Conclusions from randomized clinical trials have been constrained by sample sizes and treatment durations that may be insufficient to detect rare but serious substance-related events, questions regarding generalizability, and ethical concerns about withholding efficacious treatments (24, 25). At the same time, conclusions from observational studies have been constrained by the possibility of confounding from differences between patients who are and are not treated pharmacologically (i.e., confounding by indication) (16).

See related features. Editorial by Dr. Asherson (p. 827), Clinical Guidance (Table of Contents), CME course (p. 909), and AJP Audio (online)

Consequently, researchers have turned to observational approaches that combine large-scale health record data with designs that make within-individual comparisons across medicated and unmedicated periods, treating each patient as his or her own control (26, 27). Notably, Chang and colleagues (19) found that risk of substance-related problems was lower when ADHD patients in the Swedish population were prescribed stimulant medications. That study additionally found a long-term association between medication and lower risk for later substance-related problems, using statistical covariates but not within-individual comparisons. Given cross-national differences in diagnostic and treatment practices, the extent to which these results will generalize to other settings is unclear, and the possibility of unmeasured between-persons confounding renders the long-term associations less conclusive. In the present study, we used within-individual comparisons in a large U.S. sample to examine the extent to which stimulant and atomoxetine treatment for ADHD was associated with concurrent and long-term reductions in risk of substance-related events.

METHOD

Sample

We used data from the Truven Health MarketScan® Commercial Claims and Encounters (MarketScan) databases of de-identified inpatient, outpatient, and prescribed drug claims. As confirmed with the University of Chicago institutional review board, the analysis of MarketScan data is exempt because records are de-identified. Data were available from 2003 through 2014, although we analyzed patients identified in years 2005–2014 because emergency services coding was incomplete in earlier years. MarketScan includes data from employers and health plans in the United States. From 2005 onward, there are approximately 146 million unique enrollee observations in MarketScan, consisting of employees, individuals receiving COBRA benefits, non-Medicare retirees, and covered spouses and dependents.

We identified 2,993,887 (47.2% female; Table 1) ADHD patients, defined as enrollees who received either an ADHD diagnosis (ICD-9 codes 314.xx) or stimulant or atomoxetine ADHD medication treatment. We defined as the index date the first inpatient or outpatient diagnosis or filled prescription from 2005 onward. We followed each patient from the index date until his or her last month with any enrollment days or until December 2014. However, because substance-related problems in childhood are rare, we analyzed only those enrollment periods in which patients were at least 13 years old. We excluded all enrollment years in which patients lacked prescription drug coverage. If patients disenrolled and subsequently re-enrolled, we included continuous follow-up through the first disenrollment.

ADHD Medication

We identified stimulant medications using national drug codes for the following generic names: amphetamine salt

combination, dexamethylphenidate hydrochloride, dextroamphetamine sulfate, lisdexamfetamine dimesylate, methamphetamine hydrochloride, methylphenidate, and methylphenidate hydrochloride. Atomoxetine hydrochloride was the only included nonstimulant medication because other approved nonstimulants (i.e., extended-release clonidine and guanfacine) are frequently used as adjunctive or secondary treatments (11). We required prescription claims to have valid fill dates and days of supply (180 days or less). Medication status was defined on a monthly basis, such that a calendar month covered at least in part by a prescription (i.e., fill date plus days of supply) was considered medicated, whereas a month not covered by any prescription was considered unmedicated. Most male (83.5%) and female (87.2%) patients received ADHD medication during at least 1 follow-up month (Table 1). Among these patients, most male (89.2%) and female (90.9%) patients received stimulant medication only.

Substance-Related Events

Within-individual comparisons require a time-specific outcome. To exclude recurring treatment visits and ensure that claim dates corresponded with actual substance-related events, we counted follow-up months as having an event if they had at least one emergency department claim with any non-tobacco-related substance use disorder diagnosis (primary or otherwise). For details, see the Supplemental Method section in the data supplement that accompanies the online edition of this article.

Analytic Approach

We made three sets of comparisons using SAS, version 9.4 (SAS Institute, Cary, N.C.). We report associations separately for male and female patients because concurrent within-individual associations significantly differed by sex (long-term associations did not differ significantly). The first comparisons examined purely between-individual group differences. We used conditional logistic regression to compare the risk of at least one substance-related event from 2005 onward among ADHD patients with that among non-diagnosed, nonmedicated controls matched 1:1 on sex, calendar year of first enrollment in MarketScan, age of first enrollment, and length of enrollment in months (PROC LOGISTIC; more than 99.9% of patients could be matched). We then compared those ADHD patients who received any ADHD medication with those who never received medication from 2005 onward (controlling for year of first enrollment, age of first enrollment, and enrollment length).

The second set of comparisons examined concurrent associations between ADHD medication and substance-related events. We structured follow-up time by months and compared the risk of substance-related events during months in which patients were or were not prescribed ADHD medication (28). We analyzed substance-related events as repeating outcomes, permitting individuals to experience multiple months with events during follow-up. Events that occurred during the index month were counted only if they

occurred after the index date. In a small number of instances ($N=2,634$; 0.004% of included months), patients began new prescriptions and experienced substance-related events in the same month. In these cases, we considered patients as unmedicated for the 47.2% of months in which the patient's first substance-related event occurred before or on the same date as that patient's first prescription fill.

We began with population-level models. These models compared medicated periods with unmedicated periods, adjusting for the clustering of months within individuals using PROC SURVEYLOGISTIC. We report odds ratios with and without time-varying covariates (age, calendar year, and time since last substance-related event). Population-level models remained susceptible, however, to unmeasured confounding factors that differentiated patients who received ADHD medication from patients who did not. For our primary analyses, we therefore estimated associations using purely within-individual conditional logistic regression. These models compared months in which an individual received medication with months in which that same individual did not receive medication. Because each individual served as his or her own comparison, these models were free of confounding from all factors that were constant within the individual over time (e.g., genetics, earlier environmental influences) (29). Because the relatively small changes in years of age or calendar year that occurred during follow-up were unlikely to affect within-individual risk of substance-related events, we controlled for time since last event only.

Ten sensitivity analyses explored the robustness of the within-individual associations (see the Supplemental Method section in the data supplement). The first sensitivity analysis examined patients who already had any claims with substance use disorder diagnoses at or before the start of follow-up. The second and third analyses excluded patients who received other psychiatric medications or psychotherapy, respectively, in order to test whether the results were explained by other treatments. The fourth analysis tested whether results would persist in newly treated patients by examining a cohort with incident diagnoses of ADHD after at least 1 year of enrollment. The fifth analysis examined only the first substance-related events in this incident diagnosis cohort, which reduced the likelihood of bias due to increased medication treatment following prior substance-related events (i.e., reverse causality). The sixth analysis defined treatment gaps more conservatively by coding the first month after a medication period as still medicated. The seventh analysis examined stimulant medications only. The eighth analysis examined a broader definition of substance-related events that also included inpatient and ambulance claims. The ninth analysis estimated associations separately by age group given questions about developmental timing.

TABLE 1. Summary Statistics for ADHD Patients in a Study of ADHD Medication and Substance-Related Problems^a

Variable	Male		Female	
	N	%	N	%
Included patients	1,579,704	—	1,414,183	—
Medicated at least 1 month	1,319,349	83.5	1,233,425	87.2
At least one medication status switch	910,084	57.6	811,050	57.4
At least one substance-related event	34,655	2.2	24,196	1.7
	Median	IQR	Median	IQR
Age in years at start of follow-up	21	15–34	28	19–42
Follow-up months	16	8–33	15	8–31

^a Patients with at least one medication status switch had at least 1 month with filled prescription coverage as well as at least 1 month with no prescription coverage. Observed ages ranged from 13 to 64 years at start of follow-up, and observed follow-up ranged from 1 to 120 months. ADHD=attention deficit hyperactivity disorder; IQR=interquartile range.

Finally, to evaluate the specificity of the association to ADHD medication, the 10th analysis used selective serotonin reuptake inhibitors (SSRIs) as a negative control medication exposure (27, 30).

The third set of comparisons examined long-term (i.e., interval) associations. The interval associations tested whether medication status at a given month predicted differences in the risk of substance-related events at an interval of 2 years later. We included concurrent and lagged medication status as predictors, ensuring that the lagged association was independent of concurrent medication. We required patients to have at least 2 years of follow-up for these models and, because their lagged exposure status would otherwise be undefined, we necessarily excluded all months prior to 2 years of follow-up. We again repeated these models at the population and within-individual levels. In addition to those described above, sensitivity analyses also examined a 3-year interval and the duration of medication exposure (i.e., the cumulative months of medication during the prior 2 or 3 years).

RESULTS

Group Comparisons

Male (3.2%) and female (2.6%) ADHD patients were more likely to have at least one substance-related event than were male (1.2%; odds ratio=2.69, 95% CI=2.65–2.74) and female (0.8%; odds ratio=3.30, 95% CI=3.23–3.37) controls. Male ADHD patients who ever received medication were less likely to have substance-related events (3.1%) than were those who never received medication (4.0%; odds ratio=0.76, 95% CI=0.75–0.78). There was less difference in the odds of substance-related events among female patients who received medication (2.6%) relative to those who never received medication (2.8%; odds ratio=0.94, 95% CI=0.91–0.97). Although claims with any substance use disorder diagnosis were more common than were claims with emergency substance-related events, group differences in risk of any diagnosis were comparable (see Table S1 in the online data supplement).

TABLE 2. Concurrent Associations Between ADHD Medication and Substance-Related Events^a

Cohort	Patients (N)	Substance-Related Events (N)	Population				Within-Individual			
			Unadjusted		Adjusted		Unadjusted		Adjusted	
			Odds Ratio	95% CI	Odds Ratio	95% CI	Odds Ratio	95% CI	Odds Ratio	95% CI
Male										
All ADHD patients	1,579,704	46,676	0.68	0.67–0.70	0.81	0.79–0.83	0.79	0.77–0.81	0.65	0.64–0.67
With any prior substance use disorder	53,765	10,671	0.70	0.67–0.75	0.77	0.73–0.81	0.94	0.89–1.00	0.85	0.79–0.90
With no prior substance use disorder	1,525,939	36,005	0.74	0.72–0.76	0.86	0.84–0.88	0.76	0.74–0.78	0.61	0.59–0.63
With no other psychiatric medications	836,305	8,506	0.72	0.69–0.76	0.82	0.79–0.86	0.78	0.73–0.83	0.61	0.58–0.66
With no psychotherapy	1,129,582	17,360	0.78	0.75–0.80	0.87	0.84–0.90	0.79	0.75–0.82	0.58	0.56–0.61
Incident diagnosis cohort	304,467	9,647	0.72	0.68–0.76	0.79	0.75–0.83	0.85	0.80–0.91	0.75	0.70–0.81
First events only	304,467	7,128	0.85	0.81–0.89	0.81	0.77–0.85	0.45	0.41–0.49	–	–
Female										
All ADHD patients	1,414,183	31,842	0.81	0.79–0.84	0.89	0.87–0.92	0.84	0.81–0.86	0.69	0.67–0.71
With any prior substance use disorder	37,985	6,712	0.69	0.64–0.74	0.72	0.68–0.76	0.83	0.77–0.89	0.74	0.69–0.80
With no prior substance use disorder	1,376,198	25,130	0.89	0.86–0.91	0.97	0.94–0.99	0.84	0.81–0.87	0.67	0.65–0.70
With no other psychiatric medications	481,157	3,237	0.94	0.87–1.01	0.98	0.91–1.06	0.91	0.81–1.01	0.74	0.66–0.82
With no psychotherapy	963,074	10,694	0.97	0.93–1.02	1.01	0.97–1.05	0.90	0.85–0.95	0.66	0.62–0.70
Incident diagnosis cohort	251,990	5,685	0.87	0.82–0.93	0.89	0.84–0.94	0.94	0.87–1.03	0.87	0.80–0.95
First events only	251,990	4,406	1.01	0.95–1.07	0.96	0.90–1.02	0.57	0.52–0.64	–	–

^a Adjusted models control for age and calendar year (population models), time since last substance-related event (population and within-individual multiple events models), and months since index date (population first events models only). ADHD=attention deficit hyperactivity disorder.

Concurrent Associations Between ADHD Medication and Substance-Related Events

The second set of comparisons examined concurrent associations between receiving ADHD medication prescriptions and risk of substance-related events. At the population level, the adjusted odds of substance-related events were 19% lower among male patients (odds ratio=0.81, 95% CI=0.79–0.83) and 11% lower among female patients (odds ratio=0.89, 95% CI=0.87–0.92) during medicated months relative to unmedicated months (Table 2). More importantly, in within-individual comparisons that ruled out all time-invariant confounding effects, patients were less likely to have substance-related events during the specific months in which they received medication relative to months in which those same patients did not receive medication. Specifically, in adjusted models, ADHD medication was associated with 35% lower odds of substance-related events among men (odds ratio=0.65, 95% CI=0.64–0.67) and 31% lower odds among women (odds ratio=0.69, 95% CI=0.67–0.71). Table S2 in the online data supplement lists covariate parameter estimates.

Sensitivity analyses. Sensitivity analyses supported these associations. Among patients with prior diagnoses of substance use disorder, the concurrent associations were somewhat attenuated but remained statistically significant, except in the unadjusted model for male patients (Table 2). When we included only patients without other psychiatric

medications or psychotherapy or with incident ADHD diagnoses, the associations remained in the same direction, although unadjusted associations for female patients without other medications or incident diagnoses did not reach statistical significance. Notably, in within-individual models of first substance-related events only, medication was associated with 55% and 43% lower odds of events among male and female patients, respectively, suggesting that results from the repeated event analyses may be conservative estimates of ADHD medication associations.

Defining medication gaps more conservatively, including stimulant medication only, and including inpatient and ambulance claims as substance-related events all produced comparable associations (see Table 3, which also shows results across ages). Although their point estimates varied, the within-individual associations remained in the same direction in all age groups (and were statistically significant in adjusted models). Finally, and critically, the within-individual associations between SSRIs and substance-related events were positive, supporting the specificity of the associations for ADHD medication.

Long-Term Associations Between ADHD Medication and Substance-Related Events

The third set of comparisons examined associations with substance-related events 2 years later. Adjusted population models showed minor increases in risk of substance-related

TABLE 3. Sensitivity Analyses for Concurrent Within-Individual Associations Between ADHD Medication and Substance-Related Events^a

Sensitivity Analysis	Patients (N)	Substance-Related Events (N)	Unadjusted		Adjusted	
			Odds Ratio	95% CI	Odds Ratio	95% CI
Male						
1-month extended medicated periods	1,579,704	46,676	0.82	0.80–0.84	0.67	0.66–0.69
Stimulant medication only	1,579,704	46,676	0.80	0.78–0.82	0.66	0.64–0.68
Ambulance, inpatient, or emergency events	1,579,704	80,653	0.77	0.76–0.79	0.71	0.69–0.72
Age^b						
13–17	615,297	18,410	0.69	0.66–0.72	0.61	0.59–0.64
18–25	366,021	15,566	0.97	0.92–1.01	0.77	0.74–0.81
26–35	236,249	4,961	0.81	0.74–0.88	0.57	0.52–0.63
36–45	174,849	3,690	0.77	0.70–0.86	0.62	0.56–0.69
46+	187,288	4,049	0.69	0.62–0.76	0.55	0.49–0.61
SSRI medication	1,579,704	46,676	1.34	1.30–1.39	1.42	1.37–1.47
Female						
1-month extended medicated periods	1,414,183	31,842	0.90	0.87–0.93	0.74	0.71–0.76
Stimulant medication only	1,414,183	31,842	0.85	0.82–0.88	0.70	0.68–0.72
Ambulance, inpatient, or emergency events	1,414,183	54,420	0.79	0.77–0.81	0.71	0.69–0.73
Age^b						
13–17	299,018	8,714	0.85	0.80–0.90	0.77	0.73–0.82
18–25	333,016	9,767	0.98	0.93–1.04	0.78	0.74–0.83
26–35	266,275	4,485	0.80	0.74–0.88	0.60	0.55–0.65
36–45	241,620	4,384	0.67	0.61–0.73	0.54	0.50–0.60
46+	274,254	4,492	0.72	0.66–0.79	0.56	0.51–0.62
SSRI medication	1,414,183	31,842	1.22	1.18–1.27	1.25	1.20–1.30

^a Adjusted models control for time since last substance-related event. ADHD=attention deficit hyperactivity disorder; SSRI=selective serotonin reuptake inhibitor.

^b Age group in years at start of follow-up.

events among male (odds ratio=1.02, 95% CI=0.99–1.06) and female (odds ratio=1.10, 95% CI=1.05–1.15) patients 2 years after medicated periods. However, in adjusted within-individual models, ADHD medication predicted a 19% reduction in the odds of substance-related events 2 years later among male patients (odds ratio=0.81, 95% CI=0.78–0.85) and a 14% reduction among female patients (odds ratio=0.86, 95% CI=0.82–0.91) (see Table 4, which also presents the concurrent medication estimates from the long-term models).

Sensitivity analyses. We examined long-term associations among patients without other psychiatric medication, without psychotherapy, or with incident ADHD diagnoses. For male patients in all three groups, medication was associated with reduced long-term, within-individual risk of substance-related events. In contrast, female patients displayed attenuated long-term associations (4%–7% reductions, which were not statistically significant) among those without other medications or with incident ADHD diagnoses, but they displayed a 17% reduction in the odds of later substance-related events among those without psychotherapy. Long-term associations without adjustment for time since last event persisted among men but were attenuated among women (see Table S3 in the online data supplement).

Table 5 presents additional sensitivity analyses for the adjusted long-term associations. In male patients, we found largely comparable associations when we examined cumulative prior medication exposure, 3-year rather than 2-year time

intervals, stimulant medications only, and the broader substance-related event definition. Associations for female patients persisted in some, but not all, analyses. In addition, the adjusted associations remained in the same direction in all age groups in both sexes, although they were not all statistically significant, likely in part because of decreased power. Finally, SSRIs were associated with minimal differences in the odds of later substance-related events among male and female patients.

DISCUSSION

To our knowledge, this national U.S. study is the largest to date to examine whether stimulant and nonstimulant medication therapies for ADHD—widely used and efficacious in the short term for core ADHD symptoms—are associated with differences in risk of substance-related problems. Medication periods were generally associated with reduced risk of substance-related events. Among male patients, these associations held concurrently, in the long term, across most ages, and across multiple sensitivity analyses. Among female patients, many sensitivity analyses supported a concurrent association, but some failed to support a long-term association with reduced risk. Even when the results failed to support reductions in risk, we found almost no evidence that medication increased risk of substance-related events, including among those with pre-existing substance use disorders.

Our results join a growing pharmacoepidemiologic literature on the social and behavioral benefits and harms of

TABLE 4. Long-Term Associations Between ADHD Medication and Substance-Related Events^a

Cohort	Patients (N)	Substance-Related Events (N)	Population				Within-Individual			
			Long Term		Concurrent		Long Term		Concurrent	
			Odds Ratio	95% CI	Odds Ratio	95% CI	Odds Ratio	95% CI	Odds Ratio	95% CI
Male										
All ADHD patients	581,941	17,637	1.02	0.99–1.06	0.78	0.74–0.81	0.81	0.78–0.85	0.68	0.65–0.72
With no other psychiatric medications	278,570	2,904	0.99	0.91–1.07	0.88	0.80–0.97	0.75	0.67–0.83	0.69	0.60–0.78
With no psychotherapy	357,085	4,996	1.03	0.96–1.10	0.83	0.77–0.89	0.72	0.66–0.78	0.67	0.61–0.74
Incident diagnosis cohort	129,403	3,629	0.93	0.85–1.01	0.88	0.80–0.97	0.82	0.74–0.91	0.76	0.67–0.86
Female										
All ADHD patients	462,820	10,769	1.10	1.05–1.15	0.86	0.82–0.90	0.86	0.82–0.91	0.77	0.72–0.82
With no other psychiatric medications	128,472	897	0.98	0.84–1.14	1.12	0.96–1.30	0.93	0.75–1.14	0.84	0.66–1.06
With no psychotherapy	263,318	2,553	1.12	1.02–1.24	0.97	0.88–1.07	0.83	0.74–0.94	0.79	0.68–0.91
Incident diagnosis cohort	98,190	1,960	0.99	0.88–1.11	0.96	0.86–1.09	0.96	0.83–1.11	0.87	0.74–1.03

^a Odds ratios test long-term (2-year) and concurrent associations in simultaneous models. Models also control for age and calendar year (population models only) and time since last substance-related event (population and within-individual models). ADHD=attention deficit hyperactivity disorder.

medication treatment for ADHD. This study extended a finding of associations between stimulant medication and lower risk of substance-related problems in Sweden by demonstrating within-individual associations with not only lower concurrent risk but also lower long-term risk of substance-related events (19). Moreover, accumulating findings have also demonstrated within-individual associations with lower risk for injuries, transport accidents, criminality, depression, and suicide (26, 31–36). If these results reflect protective effects, it is possible that differing processes underlie decreased substance-related risk in the short and longer term. For example, concurrent associations may be due to decreased impulsive decision making. In the longer term, accumulating treatment may produce changes in individual behaviors and decisions that aggregate into sustained decreases in substance-related risk, and it is also possible that any benefits result from alterations in prosocial engagement (e.g., as specified by Molina and Pelham [22]). However, the apparently weaker long-term, relative to concurrent, associations suggest that at least some risk reduction may dissipate with time. Research with greater clinical detail should explore these possibilities.

The finding that long-term associations were less clear among female patients relative to male patients may suggest that ADHD medication is associated with less long-term benefit among women. However, our sample was not nationally representative, and differences in associations may reflect characteristics of the included male and female patients. For example, whereas we found more than two male adolescents for every one female adolescent, this sex ratio was reversed among those aged 26 years or older (Table 3). More female ADHD patients received other psychiatric medications and psychotherapy than did male patients (Table 2), raising the possibility that self-referral for comorbid psychiatric problems may have increased the number of included adult female patients (37). Given little prior evidence of sex

differences in associations between ADHD medication and substance-related problems (16), further investigation is warranted.

Although these data are national, large, and longitudinal, they are observational. We used multiple design features to attempt to rule out alternative explanations for the observed associations. In particular, within-individual comparisons ruled out all potential confounding factors that were constant within the individual over time (e.g., genetic substance-related liability), and we statistically adjusted for time since prior substance-related events. Sensitivity analyses supported the associations for men and, at least in the short term, for women. At the same time, our analyses could not exclude all time-varying confounding effects. Our concurrent results could be consistent, for example, with the hypothesis that life events prompt some patients to simultaneously decrease their substance involvement and enter psychiatric treatment, thereby producing noncausal medication associations. However, we do not believe that this hypothesis explains the observed long-term associations, and the finding that the associations did not hold for SSRIs may also be evidence that it does not entirely explain our results. Moreover, prior findings of associations with decreased risk of accidents and injuries are arguably less susceptible to this alternative explanation (26, 32–35). Nevertheless, lacking randomization to medication, we cannot rule out all plausible explanations.

Indeed, SSRIs were associated with increased risk of substance-related events in the short term but not in the long term. Although this pattern supports the specificity of the ADHD medication results, it also prompts questions regarding SSRIs. We believe that these associations are unlikely to represent true adverse effects but may rather reflect time-varying confounding by indication. Specifically, initiation of SSRI treatment among ADHD patients may follow the emergence of substance-related problems but still precede some events, producing a spurious positive association.

TABLE 5. Sensitivity Analyses for Long-Term Within-Individual Associations Between ADHD Medication and Substance-Related Events^a

Sensitivity Analysis	Patients (N)	Substance-Related Events (N)	Long Term		Concurrent	
			Odds Ratio	95% CI	Odds Ratio	95% CI
Male						
Age ^b (2-year interval)						
13-17	258,227	7,439	0.76	0.72-0.81	0.62	0.57-0.66
18-25	141,540	6,508	0.85	0.79-0.91	0.85	0.78-0.94
26-35	53,897	1,051	0.92	0.75-1.13	0.68	0.54-0.87
36-45	54,081	1,072	0.84	0.69-1.02	0.57	0.45-0.72
46+	74,196	1,567	0.87	0.74-1.03	0.62	0.50-0.76
Time interval						
3 years	389,529	11,597	0.79	0.75-0.83	0.69	0.65-0.74
Cumulative duration						
In last 2 years	581,941	17,637	0.80	0.76-0.84	0.72	0.69-0.76
In last 3 years	389,529	11,597	0.79	0.75-0.83	0.74	0.69-0.79
Stimulant medication only						
2-year interval	581,941	17,637	0.83	0.79-0.87	0.68	0.65-0.72
2-year cumulative			0.83	0.79-0.88	0.72	0.68-0.76
Ambulance, inpatient, or emergency events						
2-year interval	581,941	30,300	0.86	0.84-0.89	0.72	0.70-0.75
2-year cumulative			0.89	0.86-0.92	0.75	0.72-0.78
SSRI medication						
2-year interval	581,941	17,637	1.03	0.97-1.10	1.48	1.39-1.56
2-year cumulative			1.20	1.13-1.29	1.42	1.34-1.51
Female						
Age ^b (2-year interval)						
13-17	111,865	2,968	0.80	0.72-0.89	0.83	0.74-0.93
18-25	106,368	3,599	0.92	0.83-1.01	0.94	0.84-1.06
26-35	61,861	922	0.81	0.65-0.99	0.78	0.62-0.99
36-45	74,041	1,362	0.81	0.69-0.96	0.57	0.47-0.69
46+	108,685	1,918	0.93	0.81-1.07	0.53	0.45-0.63
Time interval						
3 years	293,939	6,567	0.84	0.78-0.90	0.80	0.74-0.87
Cumulative duration						
In last 2 years	462,820	10,769	0.92	0.86-0.98	0.78	0.73-0.84
In last 3 years	293,939	6,567	0.89	0.83-0.96	0.82	0.76-0.90
Stimulant medication only						
2-year interval	462,820	10,769	0.90	0.85-0.95	0.76	0.71-0.81
2-year cumulative			0.95	0.89-1.01	0.77	0.72-0.83
Ambulance, inpatient, or emergency events						
2-year interval	462,820	18,458	0.93	0.89-0.97	0.74	0.71-0.78
2-year cumulative			1.08	1.03-1.13	0.73	0.70-0.77
SSRI medication						
2-year interval	462,820	10,769	0.97	0.91-1.04	1.28	1.20-1.37
2-year cumulative			1.15	1.07-1.24	1.25	1.17-1.34

^a Odds ratios test long-term and concurrent associations in simultaneous models, controlling for time since last substance-related event. Cumulative duration associations reflect differences in odds associated with a 1-year increase in months of medication for attention deficit hyperactivity disorder (ADHD) received in the prior 2 years. SSRI=selective serotonin reuptake inhibitor.

^b Age group in years at start of long-term follow-up.

Related dynamic treatment-initiation processes have been shown to underlie associations between antidepressant treatment and suicidal behavior (38), and this pattern highlights how selection processes can differ across types of medication. Consequently, whereas the SSRI results may strengthen conclusions from this study, they highlight how such negative controls should not necessarily be viewed as definitively ruling out all alternative hypotheses.

Several additional limitations have implications for future research. First, medication treatment in these data was mostly with stimulants. It will be valuable to examine non-stimulant treatments (including extended-release clonidine and guanfacine) and stimulant types more closely (15). Future studies should also consider dosage and polypharmacy effects. Second, we were able to examine adolescents and adults, but because of the limited follow-up, these data were

not ideally suited to examining earlier childhood treatment. Given studies showing lower substance-related risk among earlier treatment initiators (20), research should examine long-term associations following childhood medication receipt. Third, although there is little existing evidence of substance-specific medication associations (19), future studies should examine whether associations differ across classes of substances (e.g., alcohol, illicit substances). Fourth, we do not know whether our results would generalize to patients without commercial health insurance. Finally, our conclusions are constrained by the limitations of claims data, including undiagnosed conditions, medications taken outside of recorded prescriptions, and, notably, prescriptions filled but not taken. As a consequence, our analyses should be interpreted as analogous to “intent-to-treat” analyses in clinical trials. It is also possible, given the size of the databases, that individuals who switched MarketScan-covered employers were included as multiple enrollee observations.

In conclusion, in a large sample of commercially insured adolescent and adult ADHD patients, ADHD medication was associated with lower concurrent risk and, at least among male patients, lower long-term risk of substance-related events. Given mixed results from clinical trials (39), our results should not be interpreted as supporting the use of ADHD medication in the treatment of substance-related problems. More broadly, our results cannot speak to the possibility of diversion or misuse of stimulants outside of treatment. However, they do join a growing evidence base of protective associations for patients receiving medication therapy. It may be useful to consider these associations in conjunction with other potential benefits and harms (e.g., growth delay) when making treatment decisions (40).

AUTHOR AND ARTICLE INFORMATION

From the Department of Psychological and Brain Sciences, Indiana University, Bloomington; the Center for Health Statistics and the Departments of Medicine and of Public Health Sciences, University of Chicago, Chicago; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; and the School of Medical Sciences, Örebro University, Örebro, Sweden.

Address correspondence to Dr. Quinn (quinnp@indiana.edu).

Supported by NIMH grant R01MH102221, by NIDA grant K99DA040727, by the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement number 602768, by the Swedish Research Council (2013–2280), by the Swedish Research Council for Health, Working Life, and Welfare (2014–2780), and by the Indiana Clinical and Translational Sciences Institute, which is funded by grant TL1TR001107 from the National Center for Advancing Translational Sciences.

The authors thank Kelsey Wiggs for assistance with table preparation.

MarketScan is a registered trademark of Truven Health Analytics. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of NIH.

Dr. Gibbons has served as an expert witness in cases involving the U.S. Department of Justice and Wyeth, Pfizer, and GlaxoSmithKline. Dr. Larsson has served as a speaker for Eli Lilly and Shire and has received a research grant from Shire. Dr. Lichtenstein has served as a speaker for Medice. The other authors report no financial relationships with commercial interests.

Received June 14, 2016, revisions received Dec. 17, 2016, and Feb. 17, 2017, accepted March 27, 2017; published online June 29, 2017.

REFERENCES

- Polanczyk GV, Salum GA, Sugaya LS, et al: Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. *J Child Psychol Psychiatry* 2015; 56:345–365
- Lahey BB, Lee SS, Sibley MH, et al: Predictors of adolescent outcomes among 4–6-year-old children with attention-deficit/hyperactivity disorder. *J Abnorm Psychol* 2016; 125:168–181
- Costello EJ, Maughan B: Annual research review: optimal outcomes of child and adolescent mental illness. *J Child Psychol Psychiatry* 2015; 56:324–341
- Charach A, Yeung E, Climans T, et al: Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. *J Am Acad Child Adolesc Psychiatry* 2011; 50:9–21
- Lee SS, Humphreys KL, Flory K, et al: Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. *Clin Psychol Rev* 2011; 31:328–341
- Sundquist J, Ohlsson H, Sundquist K, et al: Attention-deficit/hyperactivity disorder and risk for drug use disorder: a population-based follow-up and co-relative study. *Psychol Med* 2015; 45:977–983
- Skoglund C, Chen Q, Franck J, et al: Attention-deficit/hyperactivity disorder and risk for substance use disorders in relatives. *Biol Psychiatry* 2015; 77:880–886
- Quinn PD, Pettersson E, Lundström S, et al: Childhood attention-deficit/hyperactivity disorder symptoms and the development of adolescent alcohol problems: a prospective, population-based study of Swedish twins. *Am J Med Genet B Neuropsychiatr Genet* 2016; 171:958–970
- Dalsgaard S, Østergaard SD, Leckman JF, et al: Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. *Lancet* 2015; 385:2190–2196
- Phillipsen A, Jans T, Graf E, et al: Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. *JAMA Psychiatry* 2015; 72:1199–1210
- Wolraich M, Brown L, Brown RT, et al: ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics* 2011; 128:1007–1022
- Pliszka S; AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2007; 46:894–921
- Singh I: Beyond polemics: science and ethics of ADHD. *Nat Rev Neurosci* 2008; 9:957–964
- Lambert NM, Hartsough CS: Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. *J Learn Disabil* 1998; 31:533–544
- Kantak KM, Dvoskin LP: Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD. *Pharmacol Biochem Behav* 2016; 145:24–26
- Humphreys KL, Eng T, Lee SS: Stimulant medication and substance use outcomes: a meta-analysis. *JAMA Psychiatry* 2013; 70:740–749
- Molina BSG, Hinshaw SP, Eugene Arnold L, et al: Adolescent substance use in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. *J Am Acad Child Adolesc Psychiatry* 2013; 52:250–263

18. Groenman AP, Oosterlaan J, Rommelse NNJ, et al: Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. *Br J Psychiatry* 2013; 203: 112-119
19. Chang Z, Lichtenstein P, Halldner L, et al: Stimulant ADHD medication and risk for substance abuse. *J Child Psychol Psychiatry* 2014; 55:878-885
20. McCabe SE, Dickinson K, West BT, et al: Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. *J Am Acad Child Adolesc Psychiatry* 2016; 55:479-486
21. Goldstein BI: Do stimulants prevent substance use and misuse among youth with attention-deficit/hyperactivity disorder? The answer is still maybe. *J Am Acad Child Adolesc Psychiatry* 2013; 52: 225-227
22. Molina BSG, Pelham WE Jr: Attention-deficit/hyperactivity disorder and risk of substance use disorder: developmental considerations, potential pathways, and opportunities for research. *Annu Rev Clin Psychol* 2014; 10:607-639
23. Storebø OJ, Simonsen E, Gluud C: Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents. *JAMA* 2016; 315:2009-2010
24. Shaw P: Quantifying the benefits and risks of methylphenidate as treatment for childhood attention-deficit/hyperactivity disorder. *JAMA* 2016; 315:1953-1955
25. Surman CB, Monuteaux MC, Petty CR, et al: Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. *J Clin Psychiatry* 2010; 71:1612-1616
26. Dalsgaard S, Leckman JF, Mortensen PB, et al: Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. *Lancet Psychiatry* 2015; 2:702-709
27. Lichtenstein P, Halldner L, Zetterqvist J, et al: Medication for attention deficit-hyperactivity disorder and criminality. *N Engl J Med* 2012; 367:2006-2014
28. Efron B: Logistic regression, survival analysis, and the Kaplan-Meier curve. *J Am Stat Assoc* 1988; 83:414-425
29. Allison PD: *Fixed Effects Regression Models*. Thousand Oaks, Calif, Sage Publications, 2009
30. Lipsitch M, Tchetgen E, Cohen T: Negative controls: a tool for detecting confounding and bias in observational studies. *Epidemiology* 2010; 21:383-388
31. Chen Q, Sjölander A, Runeson B, et al: Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. *BMJ* 2014; 348:g3769
32. Chang Z, Lichtenstein P, D'Onofrio BM, et al: Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. *JAMA Psychiatry* 2014; 71:319-325
33. Raman SR, Marshall SW, Haynes K, et al: Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. *Inj Prev* 2013; 19:164-170
34. Man KKC, Chan EW, Coghill D, et al: Methylphenidate and the risk of trauma. *Pediatrics* 2015; 135:40-48
35. Mikolajczyk R, Horn J, Schmedt N, et al: Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. *JAMA Pediatr* 2015; 169:391-395
36. Chang Z, D'Onofrio BM, Quinn PD, et al: Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. *Biol Psychiatry* 2016; 80:916-922
37. Simon V, Czobor P, Bálint S, et al: Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *Br J Psychiatry* 2009; 194:204-211
38. Gibbons RD, Coca Perrillon M, Hur K, et al: Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents. *Pharmacoepidemiol Drug Saf* 2015; 24:208-214
39. Cunill R, Castells X, Tobias A, et al: Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. *J Psychopharmacol* 2015; 29:15-23
40. Cortese S, Holtmann M, Banaschewski T, et al: Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. *J Child Psychol Psychiatry* 2013; 54:227-246

Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis

Robert A. Rosenheck, M.D., Sue E. Estroff, Ph.D., Kyaw Sint, M.P.H., Haiqun Lin, Ph.D., Kim T. Mueser, Ph.D., Delbert G. Robinson, M.D., Nina R. Schooler, Ph.D., Patricia Marcy, B.S.N., John M. Kane, M.D., for the RAISE-ETP Investigators

Objective: Social Security Administration (SSA) disability benefits are an important source of income for people with psychoses and confer eligibility for health insurance. The authors examined the impact of coordinated specialty care on receipt of such benefits in first-episode psychosis, along with the correlates and consequences of receiving them.

Method: The Recovery After an Initial Schizophrenia Episode–Early Treatment Program (RAISE-ETP) study, a 34-site cluster-randomized trial, compared NAVIGATE, a coordinated specialty care program, to usual community care over 2 years. Receipt of SSA benefits and clinical outcomes were assessed at program entry and every 6 months for 2 years. Piecewise regression analysis was used to identify relative change in outcome trajectories after receipt of disability benefits.

Results: Among 399 RAISE-ETP participants, 36 (9%) were receiving SSA disability benefits at baseline; of the remainder,

124 (34.1%) obtained benefits during the 2-year study period. The NAVIGATE intervention improved quality of life, symptoms, and employment but did not significantly reduce the likelihood of receiving SSA disability benefits. Obtaining benefits was predicted by more severe psychotic symptoms and greater dysfunction and was followed by increased total income but fewer days of employment, reduced motivation (e.g., sense of purpose, greater anhedonia), and fewer days of intoxication.

Conclusions: A 2-year coordinated specialty care intervention did not reduce receipt of SSA disability benefits. There were some advantages for those who obtained SSA disability benefits over the 2-year treatment period, but there were also some unintended adverse consequences. Providing income supports without impeding recovery remains an important policy challenge.

Am J Psychiatry 2017; 174:886–894. doi: 10.1176/appi.ajp.2017.16111273

Controlled research on coordinated specialty care for people experiencing a first episode of psychosis has demonstrated improvements in both clinical and functional outcomes (1), including employment (2, 3). The recent Recovery After an Initial Schizophrenia Episode–Early Treatment Program (RAISE-ETP) study, a 34-site cluster-randomized trial funded by the National Institute of Mental Health (NIMH), found that a comprehensive program of pharmacologic and psychotherapeutic treatments provided in real-world settings could improve quality of life, reduce symptoms (4), and increase school and work involvement (5) as compared with usual community care.

While receipt of Social Security Administration (SSA) disability benefits is not itself a reliable indicator of disablement, these benefits are a major feature of the lives of many people living with schizophrenia, providing essential income support and conferring eligibility for health insurance. The RAISE-ETP study provides a unique opportunity to examine

the impact of coordinated specialty care on the entry of first-episode psychosis patients into the two major SSA disability programs: Social Security Disability Insurance (SSDI) and Supplemental Security Income (SSI). SSDI is an early retirement program for workers who have paid a portion of their earnings to Social Security. SSI, in contrast, is a program for people with low incomes who have not worked sufficiently to qualify for SSDI. They are referred to here, together, as SSA disability programs. SSDI confers eligibility for Medicare after a 2-year wait, and SSI generally confers eligibility for Medicaid. In 2014, some 713,000 U.S. adults received SSDI or SSI for schizophrenia (6). A 1998 survey of adults in treatment for schizophrenia in Ohio and Georgia found that 51% reported income from SSDI and 44% from SSI (7), and 57.8% of patients entering the 2005 Clinical Antipsychotic Trials of Intervention Effectiveness study reported receipt of either SSDI or SSI (8). Reliance on these programs is thus widespread among people with schizophrenia.

See related feature: *AJP Audio* (online)